Eli Lilly and Company
) is scheduled to report fourth quarter 2013 results before the
opening bell on Jan 30. Last quarter, Eli Lilly had posted an
earnings surprise of +5.71%. Let's see how things are shaping up
for this announcement.
Factors at Play
Eli Lilly has delivered positive earnings surprises in the last
four quarters with an average beat of 9.25%.
Although revenues will be impacted by the loss of U.S.
exclusivity for Cymbalta and Zyprexa, strong performance by
Humulin, Alimta, Cialis, Trajenta, Humalog and Strattera will
partially offset the negative impact of genericization. The
animal health division should also continue to perform well.
Meanwhile, cost cutting efforts and share repurchases should
boost the bottom line.
Our proven model does not conclusively show that Eli Lilly is
likely to beat earnings this quarter. That is because a stock
needs to have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
The Earnings ESP for Eli Lilly is 0.00% since the Most Accurate
Estimate is 73 cents, in line with the Zacks Consensus Estimate.
Zacks #3 Rank (Hold):
Eli Lilly's Zacks Rank #3 (Hold) has little effect on the
predictive power of ESP because the Zacks Rank #3 when combined
with a 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows that they have the right combination of elements,
i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or
) has an Earnings ESP of +2.41% and holds a Zacks Rank #3. AbbVie
will be reporting fourth quarter earnings on Jan 31.
) has an Earnings ESP of +0.33% and holds a Zacks Rank #1 (Strong
Buy). Actavis will be reporting fourth quarter earnings on Feb
) has earnings ESP of +2.27% and holds a Zacks Rank #3. Sanofi
will report fourth quarter earnings on Feb 6.
ABBVIE INC (ABBV): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.